Centre for Kidney Research, Children's Hospital, Westmead, New South Wales, Australia.
School Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
BMJ Open. 2019 Mar 12;9(3):e023918. doi: 10.1136/bmjopen-2018-023918.
The global burden of type 2 diabetes (T2DM) is steadily increasing. Experimental studies have demonstrated that a novel hormone secreted by bone cells, osteocalcin (OC), can stimulate beta-cell proliferation and improve insulin sensitivity in mice. Observational studies in humans have investigated the relationship between OC and metabolic parameters, and T2DM. Importantly, few studies have reported on the undercarboxylated form of OC (ucOC), which is the putative active form of OC suggested to affect glucose metabolism.
We will conduct a systematic review and meta-analysis to: (1) compare the levels of serum OC and ucOC between T2DM and normal glucose-tolerant controls (NGC); (2) investigate the risk ratios between serum OC and ucOC, and T2DM; (3) determine the correlation coefficient between OC and ucOC and fasting insulin levels, homeostatic model assessment-insulin resistance, haemoglobin A1c and fasting glucose levels and (4) explore potential sources of between-study heterogeneity. The secondary objective is to compare the serum OC and ucOC between pre-diabetes (PD) and NGC and between T2DM and PD.
This study will report items in line with the guidelines outlined in preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology. We will include observational studies (cohort, case-control and cross-sectional studies) and intervention studies with baseline data. Three databases (MEDLINE, EMBASE and SCOPUS) will be searched from inception until July 2018 without language restrictions. Two reviewers will independently screen the titles and abstracts and conduct a full-text assessment to identify eligible studies. Discrepancies will be resolved by consensus with a third reviewer. The risk of bias assessment will be conducted by two reviewers independently based on the Newcastle-Ottawa Scale. Potential sources of between-study heterogeneity will be tested using meta-regression/subgroup analyses. Contour-enhanced funnel plots and Egger's test will be used to identify potential publication bias.
Formal ethical approval is not required. We will disseminate the results to a peer-reviewed publication and conference presentation.
CRD42017073127.
全球 2 型糖尿病(T2DM)的负担正在稳步增加。实验研究表明,一种由骨细胞分泌的新型激素骨钙素(OC)可以刺激小鼠β细胞增殖并提高胰岛素敏感性。人类的观察性研究已经调查了 OC 与代谢参数和 T2DM 之间的关系。重要的是,很少有研究报告 OC 的未羧化形式(ucOC),这是一种被认为影响葡萄糖代谢的 OC 活性形式。
我们将进行系统评价和荟萃分析,以:(1)比较 T2DM 患者和正常糖耐量对照组(NGC)之间血清 OC 和 ucOC 的水平;(2)研究血清 OC 和 ucOC 与 T2DM 之间的风险比;(3)确定 OC 和 ucOC 与空腹胰岛素水平、稳态模型评估-胰岛素抵抗、糖化血红蛋白和空腹血糖水平之间的相关系数;(4)探索研究间异质性的潜在来源。次要目标是比较 PD 和 NGC 以及 T2DM 和 PD 之间的血清 OC 和 ucOC。
本研究将按照观察性研究系统评价和荟萃分析中流行病学报告的首选项目指南进行报告。我们将包括观察性研究(队列、病例对照和横断面研究)和具有基线数据的干预研究。从创建到 2018 年 7 月,我们将在三个数据库(MEDLINE、EMBASE 和 SCOPUS)中进行搜索,不限制语言。两名评审员将独立筛选标题和摘要,并进行全文评估以确定合格的研究。分歧将通过第三名评审员的共识解决。风险偏倚评估将由两名评审员独立根据纽卡斯尔-渥太华量表进行。通过荟萃回归/亚组分析测试研究间异质性的潜在来源。轮廓增强漏斗图和 Egger 检验将用于识别潜在的发表偏倚。
不需要正式的伦理批准。我们将向同行评审的出版物和会议报告传播结果。
PROSPERO 注册号:CRD42017073127。